FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893086430> ?p ?o ?g. }

• W2893086430 endingPage "1198" @default.
• W2893086430 startingPage "1184" @default.
• W2893086430 abstract "Medically refractory, severe, cholestasis-induced pruritus in Alagille syndrome may be improved by surgical interruption of the enterohepatic circulation. This multicenter trial (NCT02057692) tested the hypothesis that the intestinal bile acid transport inhibitor maralixibat would similarly reduce pruritus in Alagille syndrome. Thirty-seven children with Alagille syndrome were randomly assigned to double-blinded administration of placebo, 70, 140, or 280 µg/kg/day of maralixibat for 13 weeks. Pruritus was assessed by caregiver (itch-reported outcome instrument [ItchRO]) and clinician report (range, 0-4 [severe]). Liver chemistries and serum bile acids were measured. The primary outcome was the change from baseline to week 13 in ItchRO relative to placebo. In the a priori first analysis of the primary efficacy endpoint, the mean adjusted difference between participants receiving 140 or 280 µg/kg/day and placebo was -0.47 (95% confidence interval [CI], -1.14, 0.20; P = 0.16). Statistically significant decreases were observed with doses of 70 and 140 µg/kg/day (mean adjusted difference, -0.89; 95% CI, -1.70, -0.08; P = 0.032; and mean adjusted difference, -0.91; 95% CI, -1.62, -0.19; P = 0.014) but not 280 µg/kg/day (mean adjusted difference, -0.04; 95% CI, -0.94, 0.86; P = 0.44) or all doses combined (mean adjusted difference, -0.61; 95% CI, -1.24, 0.20; P = 0.055). A 1-point reduction in pruritus was more common in maralixibat-treated versus placebo-treated participants (caregiver ItchRO, 65% versus 25%; P = 0.06; clinician score, 76% versus 25%; P = 0.01). There were no significant changes in liver chemistries or bile acids relative to placebo. Adverse and serious adverse events were similar between maralixibat and placebo. Conclusion: Although the prespecified primary analyses of ItchRO were not all statistically significant, the data suggest that maralixibat is safe and may reduce pruritus in Alagille syndrome." @default.
• W2893086430 created "2018-10-05" @default.
• W2893086430 creator A5004929872 @default.
• W2893086430 creator A5011638705 @default.
• W2893086430 creator A5013644144 @default.
• W2893086430 creator A5014383358 @default.
• W2893086430 creator A5017669989 @default.
• W2893086430 creator A5017679725 @default.
• W2893086430 creator A5020707089 @default.
• W2893086430 creator A5027984281 @default.
• W2893086430 creator A5034686477 @default.
• W2893086430 creator A5036804110 @default.
• W2893086430 creator A5038339390 @default.
• W2893086430 creator A5040962057 @default.
• W2893086430 creator A5056406094 @default.
• W2893086430 creator A5058001581 @default.
• W2893086430 creator A5063054175 @default.
• W2893086430 creator A5068992178 @default.
• W2893086430 creator A5071334401 @default.
• W2893086430 creator A5084776825 @default.
• W2893086430 creator A5090960730 @default.
• W2893086430 date "2018-09-24" @default.
• W2893086430 modified "2023-10-17" @default.
• W2893086430 title "Placebo‐Controlled Randomized Trial of an Intestinal Bile Salt Transport Inhibitor for Pruritus in Alagille Syndrome" @default.
• W2893086430 cites W1612407641 @default.
• W2893086430 cites W175771670 @default.
• W2893086430 cites W1979962348 @default.
• W2893086430 cites W2022752908 @default.
• W2893086430 cites W2035367704 @default.
• W2893086430 cites W2097641440 @default.
• W2893086430 cites W2125854467 @default.
• W2893086430 cites W2134283151 @default.
• W2893086430 cites W2146626180 @default.
• W2893086430 cites W2331959986 @default.
• W2893086430 cites W2534658883 @default.
• W2893086430 cites W2561711039 @default.
• W2893086430 cites W2586480777 @default.
• W2893086430 cites W2592482187 @default.
• W2893086430 cites W2613873644 @default.
• W2893086430 cites W2734978983 @default.
• W2893086430 cites W3032310660 @default.
• W2893086430 doi "https://doi.org/10.1002/hep4.1244" @default.
• W2893086430 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6167076" @default.
• W2893086430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30288474" @default.
• W2893086430 hasPublicationYear "2018" @default.
• W2893086430 type Work @default.
• W2893086430 sameAs 2893086430 @default.
• W2893086430 citedByCount "61" @default.
• W2893086430 countsByYear W28930864302019 @default.
• W2893086430 countsByYear W28930864302020 @default.
• W2893086430 countsByYear W28930864302021 @default.
• W2893086430 countsByYear W28930864302022 @default.
• W2893086430 countsByYear W28930864302023 @default.
• W2893086430 crossrefType "journal-article" @default.
• W2893086430 hasAuthorship W2893086430A5004929872 @default.
• W2893086430 hasAuthorship W2893086430A5011638705 @default.
• W2893086430 hasAuthorship W2893086430A5013644144 @default.
• W2893086430 hasAuthorship W2893086430A5014383358 @default.
• W2893086430 hasAuthorship W2893086430A5017669989 @default.
• W2893086430 hasAuthorship W2893086430A5017679725 @default.
• W2893086430 hasAuthorship W2893086430A5020707089 @default.
• W2893086430 hasAuthorship W2893086430A5027984281 @default.
• W2893086430 hasAuthorship W2893086430A5034686477 @default.
• W2893086430 hasAuthorship W2893086430A5036804110 @default.
• W2893086430 hasAuthorship W2893086430A5038339390 @default.
• W2893086430 hasAuthorship W2893086430A5040962057 @default.
• W2893086430 hasAuthorship W2893086430A5056406094 @default.
• W2893086430 hasAuthorship W2893086430A5058001581 @default.
• W2893086430 hasAuthorship W2893086430A5063054175 @default.
• W2893086430 hasAuthorship W2893086430A5068992178 @default.
• W2893086430 hasAuthorship W2893086430A5071334401 @default.
• W2893086430 hasAuthorship W2893086430A5084776825 @default.
• W2893086430 hasAuthorship W2893086430A5090960730 @default.
• W2893086430 hasBestOaLocation W28930864301 @default.
• W2893086430 hasConcept C126322002 @default.
• W2893086430 hasConcept C141071460 @default.
• W2893086430 hasConcept C142724271 @default.
• W2893086430 hasConcept C168563851 @default.
• W2893086430 hasConcept C203092338 @default.
• W2893086430 hasConcept C204787440 @default.
• W2893086430 hasConcept C27081682 @default.
• W2893086430 hasConcept C2778593092 @default.
• W2893086430 hasConcept C2778620825 @default.
• W2893086430 hasConcept C2779399885 @default.
• W2893086430 hasConcept C2780971011 @default.
• W2893086430 hasConcept C44249647 @default.
• W2893086430 hasConcept C71924100 @default.
• W2893086430 hasConcept C90924648 @default.
• W2893086430 hasConceptScore W2893086430C126322002 @default.
• W2893086430 hasConceptScore W2893086430C141071460 @default.
• W2893086430 hasConceptScore W2893086430C142724271 @default.
• W2893086430 hasConceptScore W2893086430C168563851 @default.
• W2893086430 hasConceptScore W2893086430C203092338 @default.
• W2893086430 hasConceptScore W2893086430C204787440 @default.
• W2893086430 hasConceptScore W2893086430C27081682 @default.
• W2893086430 hasConceptScore W2893086430C2778593092 @default.
• W2893086430 hasConceptScore W2893086430C2778620825 @default.
• W2893086430 hasConceptScore W2893086430C2779399885 @default.

• next